Bioavailability Contract Manufacturing Manufacturing 
Roots Analysis
FEBRUARY 20, 2022
In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization.
Roots Analysis
MARCH 13, 2022
Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. Additionally, biopharmaceutical excipients act as bulking agents, antioxidants or preservatives.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 27, 2021
Construction of commercial drug manufacturing facility in Germany. Development of oral biosensor and contract development & manufacturing. Vektor will position itself for commercial manufacturing, pipeline development and drug formulations for critical mental health conditions.
Pharmaceutical Technology
JUNE 14, 2023
Drugs with a high potency are toxic even in small doses, and present a threat to human health, or run the risk of coming into contact with other drugs while being manufactured and compromising the quality. Of those, only 935 (34%) small molecule API facilities offered some type of containment capabilities.
Pharmaceutical Technology
APRIL 12, 2023
Evidence suggests that API manufacturing is gaining in complexity, as well as sophistication, and therefore adding to the risk profile of drug development. The ingredients used in these drugs are high potency, even at small doses, and pose a risk to both human health and cross-contamination with other drugs in a manufacturing environment.
Expert insights. Personalized for you.
52 
Let's personalize your content